,Echo Therapeutics,  
成立于1989年，总部设于美国费城，主要研发非侵入性无线透皮式动态血糖监测系统(CGM)，包括无针型Symphony  CGM System以及用于透皮给药的Prelude SkinPrep System。CGM是一种会发出微小电脉到皮肤，用感应器检测出血糖通过毛细血管的扩散，使血糖读数发送到无线手持仪器之产品。产品主要应用于医院中糖尿病人之临床的设置。

Echo Therapeutics is developing the Symphony CGM System as a non-invasive, wireless, continuous glucose monitoring system. Our target is patients who could benefit from glucose monitoring in the hospital setting, including critical care. Significant opportunity also exists for patients with diabetes to use Symphony in the outpatient setting. Echo is also developing its needle-free skin preparation component of Symphony, the Prelude® SkinPrep System, as a platform technology to enhance drug delivery of topical pharmaceuticals.